In vivo expansion of naïve CD4 +CD25 high FOXP3 + regulatory T cells in patients with colorectal carcinoma after IL-2 administration

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Beyer, Marc ^a   Schumak, Beatrix ^a   Weihrauch, Martin R ^b   Andres, Bettina ^b   Giese, Thomas ^c   Endl, Elmar ^a   Knolle, Percy A ^a   Classen, Sabine ^a   Limmer, Andreas ^a   Schultze, Joachim L ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; PEPTIDE VACCINE; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TNFRSF18 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; AGED; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

MURINAE;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; CTLA-4 ANTIGEN; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 84856039913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030422     Document Type: Article

References (58)

1. Sakaguchi S, Miyara M, Costantino CM, Hafler DA, (2010) FOXP3+ regulatory T cells in the human immune system. Nature reviews Immunology 10: 490-500.
2. Sakaguchi S, (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352.
3. Shevach EM, (2001) Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193: F41-46.
4. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, et al. (2001) Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 31: 1122-1131.
5. Vukmanovic-Stejic M, Zhang Y, Cook JE, Fletcher JM, McQuaid A, et al. (2006) Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 116: 2423-2433.
6. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, et al. (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192: 303-310.
7. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, et al. (2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323.
8. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, et al. (2007) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19: 345-354.
9. Tran DQ, Ramsey H, Shevach EM, (2007) Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110: 2983-2990.
10. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, et al. (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470: 548-553.
11. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, et al. (2009) Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer cell 15: 114-123.
12. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, et al. (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34: 336-344.
13. Shimizu J, Yamazaki S, Sakaguchi S, (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218.
14. Beyer M, Schultze JL, (2006) Regulatory T cells in cancer. Blood 108: 804-811.
15. Beyer M, Schultze JL, (2008) Immunoregulatory T cells: role and potential as a target in malignancy. Curr Oncol Rep 10: 130-136.
16. Beyer M, Schultze JL, (2009) Regulatory T cells: major players in the tumor microenvironment. Current pharmaceutical design 15: 1879-1892.
17. Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, et al. (2007) Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. International journal of cancer Journal international du cancer 120: 2723-2733.
18. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, et al. (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112: 610-618.
19. Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, et al. (2006) CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 1: e129.
20. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, et al. (2008) Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 57: 813-821.
21. Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, et al. (2007) Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 7: 7.
22. Thornton AM, Shevach EM, (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188: 287-296.
23. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M, (2005) A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 115: 1953-1962.
24. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, et al. (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30: 899-911.
25. Santner-Nanan B, Seddiki N, Zhu E, Quent V, Kelleher A, et al. (2008) Accelerated age-dependent transition of human regulatory T cells to effector memory phenotype. Int Immunol 20: 375-383.
26. Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, et al. (2006) Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 107: 2830-2838.
27. Beyer M, Schultze JL, (2007) CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype. J Clin Oncol 25: 2628-2630.
28. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, et al. (2006) In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107: 3940-3949.
29. Beyer M, Classen S, Endl E, Kochanek M, Weihrauch MR, et al. (2011) Comparative Approach to Define Increased Regulatory T Cells in Different Cancer Subtypes by Combined Assessment of CD127 and FOXP3. Clinical & developmental immunology 2011: 734036.
30. Hori S, Haury M, Lafaille JJ, Demengeot J, Coutinho A, (2002) Peripheral expansion of thymus-derived regulatory cells in anti-myelin basic protein T cell receptor transgenic mice. Eur J Immunol 32: 3729-3735.
31. Kasow KA, Chen X, Knowles J, Wichlan D, Handgretinger R, et al. (2004) Human CD4+CD25+ regulatory T cells share equally complex and comparable repertoires with CD4+CD25- counterparts. J Immunol 172: 6123-6128.
32. Malek TR, Bayer AL, (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4: 665-674.
33. Bayer AL, Yu A, Adeegbe D, Malek TR, (2005) Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med 201: 769-777.
34. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY, (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142-1151.
35. Setoguchi R, Hori S, Takahashi T, Sakaguchi S, (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723-735.
36. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ, (2002) Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 196: 851-857.
37. Ahmadzadeh M, Rosenberg SA, (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107: 2409-2414.
38. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, et al. (2005) Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 11: 1238-1243.
39. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, et al. (2006) Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24: 1169-1177.
40. Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, et al. (2008) Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 26: 2292-2298.
41. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, et al. (2007) Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 67: 7487-7494.
42. van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, et al. (2007) Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 13: 2100-2108.
43. Jensen HK, Donskov F, Nordsmark M, Marcussen N, von der Maase H, (2009) Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res 15: 1052-1058.
44. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, et al. (2005) Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23: 8950-8958.
45. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, et al. (2008) Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine+FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial). Clin Cancer Res 14: 4192-4199.
46. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, et al. (2005) Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106: 2018-2025.
47. Baecher-Allan C, Viglietta V, Hafler DA, (2004) Human CD4+CD25+ regulatory T cells. Semin Immunol 16: 89-98.
48. Tosello V, Odunsi K, Souleimanian NE, Lele S, Shrikant P, et al. (2008) Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clin Immunol 126: 291-302.
49. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK, (2005) Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 202: 1375-1386.
50. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM, (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172: 6519-6523.
51. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ, (2007) CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8: 1353-1362.
52. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, et al. (2006) IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108: 1571-1579.
53. Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, et al. (2005) Persistence of naive CD45RA+ regulatory T cells in adult life. Blood.
54. Watanabe N, Wang YH, Lee HK, Ito T, Wang YH, et al. (2005) Hassall's corpuscles instruct dendritic cells to induce CD4(+)CD25(+) regulatory T cells in human thymus. Nature 436: 1181-1185.
55. Burchill MA, Yang JY, Vogtenhuber C, Blazar BR, Farrar MA, (2007) IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3(+) regulatory T cells. Journal of Immunology 178: 280-290.
56. Weihrauch MR, Ansen S, Jurkiewicz E, Geisen C, Xia Z, et al. (2005) Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 11: 5993-6001.
57. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM, (2006) Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 36: 2139-2149.
58. Chu YW, Memon SA, Sharrow SO, Hakim FT, Eckhaus M, et al. (2004) Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 104: 1110-1119.